JP2016517446A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517446A5
JP2016517446A5 JP2016503417A JP2016503417A JP2016517446A5 JP 2016517446 A5 JP2016517446 A5 JP 2016517446A5 JP 2016503417 A JP2016503417 A JP 2016503417A JP 2016503417 A JP2016503417 A JP 2016503417A JP 2016517446 A5 JP2016517446 A5 JP 2016517446A5
Authority
JP
Japan
Prior art keywords
seq
composition
patient
mucus
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503417A
Other languages
English (en)
Japanese (ja)
Other versions
JP6672139B2 (ja
JP2016517446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/030545 external-priority patent/WO2014145735A2/en
Publication of JP2016517446A publication Critical patent/JP2016517446A/ja
Publication of JP2016517446A5 publication Critical patent/JP2016517446A5/ja
Application granted granted Critical
Publication of JP6672139B2 publication Critical patent/JP6672139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503417A 2013-03-15 2014-03-17 粘液の粘性の正常化のための組成物 Active JP6672139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792198P 2013-03-15 2013-03-15
US61/792,198 2013-03-15
PCT/US2014/030545 WO2014145735A2 (en) 2013-03-15 2014-03-17 Product and process for mucus viscosity normalization

Publications (3)

Publication Number Publication Date
JP2016517446A JP2016517446A (ja) 2016-06-16
JP2016517446A5 true JP2016517446A5 (https=) 2017-04-20
JP6672139B2 JP6672139B2 (ja) 2020-03-25

Family

ID=51527945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503417A Active JP6672139B2 (ja) 2013-03-15 2014-03-17 粘液の粘性の正常化のための組成物

Country Status (11)

Country Link
US (4) US9168290B2 (https=)
EP (1) EP2968481B1 (https=)
JP (1) JP6672139B2 (https=)
KR (2) KR20160007496A (https=)
CN (1) CN105188738B (https=)
AU (1) AU2014232520B2 (https=)
CA (1) CA2906868A1 (https=)
IL (1) IL241320B (https=)
MX (1) MX377653B (https=)
RU (1) RU2750211C2 (https=)
WO (1) WO2014145735A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9168290B2 (en) * 2013-03-15 2015-10-27 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
CN106868090B (zh) * 2017-03-28 2020-09-29 王绪友 一种医学检验用痰液处理方法
CN107630065A (zh) * 2017-11-02 2018-01-26 蔡慧娜 一种在支原体液体培养时使标本均匀分散的方法
US20210213134A1 (en) * 2018-05-17 2021-07-15 Orpro Therapeutics, Inc. Thiol-based multivalent drug delivery compositions
WO2021138682A1 (en) * 2020-01-03 2021-07-08 Orpro Therapeutics, Inc. Compositions having thioredoxin activity and related methods
CN115200954B (zh) * 2022-06-28 2025-05-06 珠海大略科技有限公司 一种降低唾液粘度的方法及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
US3502779A (en) 1966-08-18 1970-03-24 Calbiochem Process of mucolysis
US3683069A (en) * 1970-02-19 1972-08-08 Michel Hooreman Enzymatic products which optimize the viscosity of mucuses and their applications
US4738841A (en) * 1985-08-28 1988-04-19 Repligen Corporation Use of thioredoxin, thioredoxin-derived, or thioredoxin-like dithiol peptides in hair care preparations
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
SE8903003D0 (sv) 1989-09-12 1989-09-12 Astra Ab Novel medical use
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5908611A (en) 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
AU3643497A (en) 1996-06-28 1998-01-21 National Jewish Center For Immunology And Respiratory Medicine Use of thioredoxin-like molecules for induction of mnsod to treat oxidative damage
JPH10191977A (ja) 1997-01-14 1998-07-28 Oriental Yeast Co Ltd チオレドキシン改変体及び該改変体を含むａｐ−１の転写活性能を増強する因子
DE19711052C2 (de) 1997-03-03 1999-09-23 Hans Rommelspacher Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure als Mukolytikum
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
US5925334A (en) 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
CN103641892B (zh) 2001-03-29 2015-06-17 药物协和公司 用于治疗组织炎症和癌变的鸟苷酸环化酶受体激动剂
US7071307B2 (en) 2001-05-04 2006-07-04 Syngenta Participations Ag Nucleic acids and proteins with thioredoxin reductase activity
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20060148057A1 (en) * 2002-08-02 2006-07-06 Wang Min Thioredoxin mutants and uses thereof
CN1694726A (zh) * 2002-09-10 2005-11-09 国家杰威什医疗及研究中心 用于液化粘液或痰液的产品和方法
CA2498581C (en) 2002-09-10 2019-03-19 National Jewish Medical And Research Center Thioredoxin composition and uses thereof for liquefaction of mucus or sputum
US20090075871A2 (en) 2003-03-31 2009-03-19 National Institute Of Advanced Industrial Science And Technology Modified Thioredoxin
RU2253484C1 (ru) * 2003-09-30 2005-06-10 Российский научный центр восстановительной медицины и курортологии Министерства здравоохранения Российской Федерации Способ лечения хронического бронхолегочного процесса при врожденных пороках развития легких у детей
WO2005094269A2 (en) 2004-03-24 2005-10-13 National Jewish Medical And Research Center Mucolytic and anti-elastase compounds and methods of use thereof
US20090203586A1 (en) 2004-06-11 2009-08-13 Syngenta Limited Method for ameliorating an inflammatory skin condition
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
GB0503640D0 (en) 2005-02-22 2005-03-30 Syngenta Ltd Improvements in or relating to organic compounds
US9168290B2 (en) 2013-03-15 2015-10-27 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization
US20210213134A1 (en) 2018-05-17 2021-07-15 Orpro Therapeutics, Inc. Thiol-based multivalent drug delivery compositions
WO2021138682A1 (en) 2020-01-03 2021-07-08 Orpro Therapeutics, Inc. Compositions having thioredoxin activity and related methods

Similar Documents

Publication Publication Date Title
JP2016517446A5 (https=)
Fröhlich et al. Oral inhalation for delivery of proteins and peptides to the lungs
Weers et al. Formulation design of dry powders for inhalation
Cryan et al. In vivo animal models for drug delivery across the lung mucosal barrier
JP2012176990A5 (https=)
JP2015517489A5 (https=)
US20230190685A1 (en) Formulation
RU2011114078A (ru) Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
EP2277505A3 (en) Mucoactive agents for treating a pulmonary disease
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
WO2021198115A1 (en) Treatment
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
RU2010108640A (ru) Новая комбинация терапевтических агентов
JP2017501140A5 (https=)
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
JP2012503668A5 (https=)
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
EP4665372A1 (en) New multi-functional oligopeptides
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
Kaur Pulmonary drug delivery system: Newer patents
WO2015049519A3 (en) Method and apparatus for making compositions for pulmonary administration
RU2012156256A (ru) Факторы трилистника (tff) для лечения хронических заболеваний легких
UY28590A1 (es) Procedimiento para la preparación de nuevas sales de tiotropio, nuevas sales de tiotropio como tales, así como las formulaciones medicamentosas que las contienen.
RU2014136096A (ru) Лекарственное средство для лечения и профилактики заболеваний верхних и нижних дыхательных путей различной этиологии, его применение и метод лечения на его основе